spacer
home > pmps > spring 2007 > lyophilisation closures
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Lyophilisation Closures

With no universal lyophilisation closure on the market, Douglas Cusato at Helvoet Pharma reiterates the importance of compendial, functional and stability tests

LYOPHILISED PHARMACEUTICALS

During the design of modern day pharmaceuticals, researchers have to consider a wide range of variables. A simple variable that needs to be considered is the colour of products and their packaging components for identification and marketing. One of the more difficult variables is the type of closure system a product will be packaged in, and how it will be administered. However, most modern day protein/peptide-based pharmaceuticals have been mainly confined to lyophilisation packaging systems. This is due to protein’s inability to maintain a suitable shelf-life in other pharmaceutical packaging environments, such as aqueous mediums in prefilled syringes and vials. Furthermore, oral administration of protein-based pharmaceuticals is not accomplishable, due to the extremely high acidic environment of the stomach.

LYOPHILISATION CLOSURES

Historically, the function of rubber closures was limited to maintaining a seal in the vial or barrel opening, confining a pharmaceutical within a vial or prefilled syringe and permitting proper removal of the pharmaceutical via a hypodermic needle. More recently the rubber closure has become an intricate part of the pharmaceutical closure system, especially regarding lyophilisation stoppers. Modern day lyophilisation stoppers are required to have a low gas and vapour permeability, low affinity to hold moisture, stability in the halfway-down position and vents which are large enough to allow efficient mass transfer during the lyophilisation process.

Also of importance, the closure must be able to establish and maintain seal integrity before and after crimping the aluminum cap. Along with all of these characteristics, a lyophilisation stopper needs to be universally compatible with different lyophilisation machinery. This article discusses topics associated with lyophilisation closures – including compound properties, closure design and coatings.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Douglas Cusato is a Technical Support Manager with Helvoet Pharma. He joined Helvoet Pharma in August 2006 and is responsible for assisting customers with technical issues such as extractables and leachables, rubber formulation, closure design recommendations and closure coatings. During his academic career, Douglas studied protein to substrate interactions and the proteomic and transcriptomic responses of stressed bacteria. He holds a Bachelor degree in Chemistry from Rutgers University, Camden, New Jersey with an emphasis in Biochemistry. In September 2007 he will begin his Master’s degree at Rutgers focusing on Polymer/Material Chemistry. Prior to joining Helvoet Pharma, Douglas was a co-founder of Metabolic Adaptations, a nutrition company specialising in developing athletic sports drinks; he led the product development and packaging division for several years.
spacer
Douglas Cusato
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Breakthrough in the global battle against polio: AJ Vaccines granted WHO prequalification for new polio vaccine

Despite ongoing concerted efforts to eradicate polio, it appears to be on the rise again with more cases registered in 2019 than 2018. Looking ahead, AJ Vaccines’ dose sparing technology provides a significant opportunity to expand supply, with the potential to deliver up to 100 million doses over the five-year period 2020-2024 to help meet the currently unmet global demand for inactivated polio vaccines.
More info >>

White Papers

galenIQ - The smart excipient

BENEO GmbH

galenIQ combines a multitude of outstanding characteristics and is suitable for a wide range of pharmaceutical applications. galenIQ can be used as more than just a bulk excipient. It also serves as an anti-caking agent, anti-humectant agent, stabilizer or oral care and taste agent to mention just a few additional functions.
More info >>

 
Industry Events

World Vaccine Congress Washington

27-29 September 2020, Walter E Washington Convention Center, Washington, US

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement